OBJECTIVES: The cytokines interleukin (IL)-1beta and IL-6 are modulators of the neuroimmune axis and have been implicated in neuronal cell death cascades after ischemia or infection. Previous work has shown that some cross-species conservation exists between human and rodent blood-brain barrier (BBB) transport systems. To further assess cross-species conservation of cytokine transport across the BBB, the current studies investigated permeability and inhibition of ovine IL-1beta and IL-6 in the mouse. METHODS: IL-1beta or IL-6 was radioactively labeled with (131)I and injected into the jugular vein at time zero. A subset of mice received 1 or 3 microg/mouse of an unlabeled ovine or murine cytokine (IL-1beta or IL-6) to assess self- and/or cross-inhibition of transport. Permeability was assessed using multiple-regression analysis. RESULTS: There was a significant linear relationship for both ovine (131)I-IL-1beta and (131)I-IL-6 between brain/serum ratios and exposure time, indicating BBB permeability. Inclusion of 3 microg/mouse unlabeled ovine IL-1beta or IL-6 significantly reduced the transport of ovine (131)I-IL-1beta or (131)I-IL-6, respectively, across the BBB. Transport of both ovine (131)I-IL-1beta and (131)I-IL-6 was significantly inhibited by 1 microg/mouse of murine IL-1beta or IL-6, respectively. In contrast, 1 microg/mouse of unlabeled ovine IL-1beta or IL-6 did not inhibit the transport of murine (131)I-IL-1beta or (131)I-IL-6. CONCLUSIONS: Ovine IL-1beta and IL-6 cross the mouse BBB by saturable transport. Inhibition of transport by murine homologs indicates that both species use the same transport mechanisms. Conversely, an inability of ovine cytokines to significantly inhibit the transport of murine cytokines indicates that mouse BBB has a lower affinity for ovine than murine cytokines. Knowledge of species-conserved BBB transport mechanisms may facilitate the development of novel animal models of central nervous system pathogenesis. Copyright 2010 S. Karger AG, Basel.
OBJECTIVES: The cytokines interleukin (IL)-1beta and IL-6 are modulators of the neuroimmune axis and have been implicated in neuronal cell death cascades after ischemia or infection. Previous work has shown that some cross-species conservation exists between human and rodent blood-brain barrier (BBB) transport systems. To further assess cross-species conservation of cytokine transport across the BBB, the current studies investigated permeability and inhibition of ovine IL-1beta and IL-6 in the mouse. METHODS:IL-1beta or IL-6 was radioactively labeled with (131)I and injected into the jugular vein at time zero. A subset of mice received 1 or 3 microg/mouse of an unlabeled ovine or murine cytokine (IL-1beta or IL-6) to assess self- and/or cross-inhibition of transport. Permeability was assessed using multiple-regression analysis. RESULTS: There was a significant linear relationship for both ovine (131)I-IL-1beta and (131)I-IL-6 between brain/serum ratios and exposure time, indicating BBB permeability. Inclusion of 3 microg/mouse unlabeled ovine IL-1beta or IL-6 significantly reduced the transport of ovine (131)I-IL-1beta or (131)I-IL-6, respectively, across the BBB. Transport of both ovine (131)I-IL-1beta and (131)I-IL-6 was significantly inhibited by 1 microg/mouse of murineIL-1beta or IL-6, respectively. In contrast, 1 microg/mouse of unlabeled ovine IL-1beta or IL-6 did not inhibit the transport of murine (131)I-IL-1beta or (131)I-IL-6. CONCLUSIONS: Ovine IL-1beta and IL-6 cross the mouse BBB by saturable transport. Inhibition of transport by murine homologs indicates that both species use the same transport mechanisms. Conversely, an inability of ovine cytokines to significantly inhibit the transport of murine cytokines indicates that mouse BBB has a lower affinity for ovine than murine cytokines. Knowledge of species-conserved BBB transport mechanisms may facilitate the development of novel animal models of central nervous system pathogenesis. Copyright 2010 S. Karger AG, Basel.
Authors: Katherine H Petersson; Halit Pinar; Edward G Stopa; Grazyna B Sadowska; R Choudary Hanumara; Barbara S Stonestreet Journal: Pediatr Res Date: 2004-08-19 Impact factor: 3.756
Authors: Katherine H Petersson; Halit Pinar; Edward G Stopa; Ronald A Faris; Grazyna B Sadowska; R Choudry Hanumara; Barbara S Stonestreet Journal: Pediatr Res Date: 2002-06 Impact factor: 3.756
Authors: C J March; B Mosley; A Larsen; D P Cerretti; G Braedt; V Price; S Gillis; C S Henney; S R Kronheim; K Grabstein Journal: Nature Date: 1985 Jun 20-26 Impact factor: 49.962
Authors: Aparna Patra; Xiaodi Chen; Grazyna B Sadowska; Jiyong Zhang; Yow-Pin Lim; James F Padbury; William A Banks; Barbara S Stonestreet Journal: Neuroscience Date: 2017-01-09 Impact factor: 3.590
Authors: Aric F Logsdon; Michelle A Erickson; Xiaodi Chen; Joseph Qiu; Yow-Pin Lim; Barbara S Stonestreet; William A Banks Journal: J Cereb Blood Flow Metab Date: 2019-06-24 Impact factor: 6.200
Authors: Konasale M Prasad; Ashley M Burgess; Matcheri S Keshavan; Vishwajit L Nimgaonkar; Jeffrey A Stanley Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2016-11
Authors: Linda L Carpenter; Cyrena E Gawuga; Audrey R Tyrka; Janet K Lee; George M Anderson; Lawrence H Price Journal: Neuropsychopharmacology Date: 2010-09-29 Impact factor: 7.853
Authors: Grazyna B Sadowska; Xiaodi Chen; Jiyong Zhang; Yow-Pin Lim; Erin E Cummings; Oleksandr Makeyev; Walter G Besio; John Gaitanis; James F Padbury; William A Banks; Barbara S Stonestreet Journal: J Cereb Blood Flow Metab Date: 2015-06-17 Impact factor: 6.200
Authors: Samantha K Barton; Annie R A McDougall; Jacqueline M Melville; Timothy J M Moss; Valerie A Zahra; Tammy Lim; Kelly J Crossley; Graeme R Polglase; Mary Tolcos Journal: J Physiol Date: 2015-10-08 Impact factor: 5.182